Global Next Generation Sequencing (NGS) Market, By Product (Instruments, Consumables, Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research, Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes, Hospital & Clinics) – Industry Trends and Forecast to 2030.
Next Generation Sequencing (NGS) Market Analysis and Size
Continuous advancements in NGS technologies have led to increased speed, accuracy, and cost-efficiency. These improvements have made NGS more accessible and attractive to researchers and clinicians. NGS is widely used in genomics research for applications such as whole-genome sequencing, transcriptomics, epigenomics, and metagenomics. Researchers are using NGS to gain insights into genetic variations, gene expression, and the functional genomics of diseases, which drives demand for these technologies.
Data Bridge Market Research analyzes that the next generation sequencing (NGS) market, which was USD 7,008.17 million in 2022, is likely to reach USD 31,417.25 million by 2030 and is expected to undergo a CAGR of 17.1% during the forecast period. “Instruments” dominates the product segment of the next generation sequencing (NGS) market due to the growing demand for NGS.
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Instruments, Consumables, Services), Applications (Diagnostics, Biomarker Discovery, Precision Medicine, Drug Discovery, Agriculture and Animal Research, Others), End User (Pharmaceutical & Biotechnology Companies, Research Centers & Academic and Government Institutes, Hospital & Clinics)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands, Rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Rest of Middle East And Africa
|
|
Market Players Covered
|
Agilent Technologies, Inc.(U.S.), ThermoFisher Scientific, Inc.(U.S.), QIAGEN (Netherlands), Illumina, Inc.(U.S.), Bio-Rad Laboratories, Inc. (U.S.), Roche Sequencing (A subsidiary of F. Hoffman La Roche) (Switzerland), BGI (A subsidiary of BGI Group) (China), Oxford Nanopore Technologies plc (U.K.), MACROGEN CO., LTD.(South Korea), DNASTAR (U.S.), Geneious, Partek , Incorporated (U.S.), PerkinElmer Inc.(U.S.), Takara Bio Inc. (Japan), bioMérieux SA (France), Pacific Biosciences of California, Inc.(U.S.), GENEWIZ (U.S.), 10x Genomics (U.S.), New England Biolabs (U.S.), Hamilton Company (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The global NGS market can be defined as the overall economic activity related to the development, manufacturing, and application of next-generation sequencing technologies and services. Key components of the NGS market include sequencing platforms, consumables (reagents and kits), and services (sequencing services, data analysis, and storage). Factors driving the growth of the global NGS market include advancements in sequencing technologies, decreasing sequencing costs, increased funding for genomics research, and the expanding applications of NGS in areas such as personalized medicine, oncology, agriculture, and microbiology.
Global Next Generation Sequencing (NGS) market Dynamics
Drivers
- Advancements in sequencing technologies
Technological improvements have significantly increased the speed at which DNA and RNA sequences can be determined. Next-generation sequencing platforms can now process a larger number of samples simultaneously, leading to higher throughput. This is particularly valuable in research and clinical applications where large-scale sequencing is required, such as in genomics studies and diagnostic testing. Continuous innovations in NGS platforms have led to improved speed, accuracy, and cost-efficiency. These advancements make NGS more accessible and attractive to researchers and healthcare professionals.
- Awareness of precision medicine
In oncology, precision medicine is a rapidly growing field. NGS is used to analyze the genomic alterations in cancer cells, which can help identify potential targets for treatment and predict the response to specific therapies. The increasing awareness of targeted therapies for cancer treatment drives the demand for NGS. Growing awareness of the potential of NGS for personalized medicine has boosted its adoption. NGS enables the development of treatment strategies tailored to an individual's genetic profile, which is seen as a key component of the future of healthcare.
Opportunity
- Integration of Multi-Omics Data
The integration of genomics, transcriptomics, epigenomics, and metagenomics data using NGS provides comprehensive insights into complex biological systems. This opportunity supports a deeper understanding of health and disease. Advances in NGS technologies enable the integration of multiple omics data, including genomics, transcriptomics, epigenomics, and metagenomics. Researchers can gain a more comprehensive view of biological systems, leading to better insights and discoveries.
Restraints/Challenges
- Lack of Standardization in Reporting
The interpretation and reporting of NGS results can vary among laboratories and institutions. Standardizing reporting practices and ensuring consistency in the clinical interpretation of genomic data is challenging. Without standardized reporting practices, there can be significant variability in how NGS results are interpreted and reported by different laboratories and institutions. This variability can lead to inconsistencies in clinical interpretations, making it challenging for healthcare providers to make informed decisions based on NGS data.
Recent Developments
- In January 2021, Merus N.V.; a clinical stage immuno-oncology company; collaborated with National Cancer Center, Japan and Erasmus University Medical Center, Netherlands to evaluate its HER2/3-targeting bispecific antibody in solid tumors
- In March 2020, Agilent Technologies, Inc. launched three new microarrays to address the requirements of prenatal and postnatal research in cytogenetic laboratories. These new products launched by the company increases its NGS product portfolio leading to increased demand for its products in future
- In February 2020, Twist Bioscience launched its new NGS solution named Twist Targeted Methylation Sequencing Solution which aids to study methylation pattern changes in the wide range of research fields including cancer, epigenetics and non-invasive prenatal testing. This new product launch by the company has increased its credibility in the market
Global Next Generation Sequencing (NGS) Market Scope
The next generation sequencing (NGS) market is segmented on the basis of product, application and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Instruments
- Consumables
- Services
Application
- Diagnostics
- Biomarker Discovery
- Precision Medicine
- Drug Discovery
- Agriculture and Animal Research
- Others
End User
- Pharmaceutical & Biotechnology Companies
- Research Centers & Academic Government Institutes
- Hospital & Clinics
Global Next Generation Sequencing (NGS) market Regional Analysis/Insights
The next generation sequencing (NGS) market is analyzed and market size insights and trends are provided by country, product, application, and end user as referenced above.
The countries covered in the next generation sequencing (NGS) market report are U.S., Canada, Mexico, Germany, U.S., Canada, Mexico, Germany, U.K., Italy, France, Spain, Switzerland, Russia, Turkey, Belgium, Netherlands, rest of Europe, Japan, China, South Korea, India, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa and rest of Middle East And Africa.
North America is expected to dominate the market due to the presence of advanced healthcare infrastructure.
Asia-Pacific is expected to grow during the forecast period due to surge in regional investments.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The next generation sequencing (NGS) market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the next generation sequencing (NGS) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the next generation sequencing (NGS) market.
Competitive Landscape and Next Generation Sequencing (NGS) market Share Analysis
The next generation sequencing (NGS) market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the next generation sequencing (NGS) market.
Some of the major players operating in the next generation sequencing (NGS) market are:
- Agilent Technologies, Inc.(U.S.)
- ThermoFisher Scientific, Inc.(U.S.)
- QIAGEN (Netherlands)
- Illumina, Inc.(U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Roche Sequencing (A subsidiary of F. Hoffman La Roche) (Switzerland)
- BGI (A subsidiary of BGI Group) (China)
- Oxford Nanopore Technologies plc (U.K.)
- MACROGEN CO., LTD.(South Korea)
- DNASTAR (U.S.)
- Geneious, Partek , Incorporated (U.S.)
- PerkinElmer Inc.(U.S.)
- Takara Bio Inc. (Japan)
- bioMérieux SA (France)
- Pacific Biosciences of California, Inc.(U.S.)
- GENEWIZ (U.S.)
- 10x Genomics (U.S.)
- New England Biolabs (U.S.)
- Hamilton Company (U.S.)
SKU-